Diagnosis and treatment of latent infection with Mycobacterium tuberculosis

Respirology

Volumn 18, Issue 2, 2013, Pages 205-216

  Chee, Cynthia Bin Eng ^a   Sester, Martina ^b   Zhang, Wenhong ^d   Lange, Christoph ^c  

^a TAN TOCK SENG HOSPITAL   (Singapore)

^b SAARLAND UNIVERSITY   (Germany)

^c RESEARCH CENTER BORSTEL   (Germany)

^d FUDAN UNIVERSITY   (China)

Author keywords

interferon release assay; latent infection with Mycobacterium tuberculosis; prevention; tuberculin skin test; tuberculosis

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; ISONIAZID; RIFAMPICIN; RIFAPENTINE; TUMOR NECROSIS FACTOR ALPHA;

ABDOMINAL DISCOMFORT; ALLERGIC REACTION; ANTIGEN PRESENTING CELL; CD4 LYMPHOCYTE COUNT; CLINICAL PRACTICE; CYTOKINE RELEASE; DISEASE COURSE; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOPATHOLOGY; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; LIVER TOXICITY; LUNG ALVEOLUS MACROPHAGE; MEMORY T LYMPHOCYTE; META ANALYSIS (TOPIC); NAUSEA; NONHUMAN; PATHOGENESIS; PATIENT COMPLIANCE; PHAGOSOME; PREDICTIVE VALUE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; SILICOSIS; SKIN INDURATION; SPUTUM EXAMINATION; SYSTEMATIC REVIEW (TOPIC); THORAX RADIOGRAPHY; TUBERCULIN TEST; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT; VOMITING;

ANTITUBERCULAR AGENTS; DISEASE PROGRESSION; DRUG THERAPY; HUMANS; IMMUNOLOGIC TESTS; LATENT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; RISK FACTORS; TUBERCULIN TEST; TUBERCULOSIS, PULMONARY;

EID: 84872893549     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/resp.12002     Document Type: Review

References (114)

1. World Health Organization. Tuberculosis. Fact sheet °104. 2012. [Accessed 9 Sep 2012.] Available from URL: http://www.who.int/mediacentre/ factsheets/fs104/en/
2. Comstock GW, Livesay VT, Woolpert SF,. The prognosis of a positive tuberculin reaction in childhood and adolescence. Am. J. Epidemiol. 1974; 99: 131-138.
3. Rangaka MX, Wilkinson KA, Glynn JR, et al. Predictive value of interferon-gamma release assays for incident active tuberculosis: A systematic review and meta-analysis. Lancet Infect. Dis. 2012; 12: 45-55.
4. Mack U, Migliori GB, Sester M, et al. LTBI: latent tuberculosis infection or lasting immune responses to M. tuberculosis? A TBNET consensus statement. Eur. Respir. J. 2009; 33: 956-973.
5. Erkens CG, Kamphorst M, Abubakar I, et al. Tuberculosis contact investigation in low prevalence countries: A European consensus. Eur. Respir. J. 2010; 36: 925-949.
6. Young DB, Gideon HP, Wilkinson RJ,. Eliminating latent tuberculosis. Trends Microbiol. 2009; 17: 183-188.
7. Barry CE, 3rd, Boshoff HI, Dartois V, et al. The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. Nat. Rev. Microbiol. 2009; 7: 845-855.
8. Pai M,. Spectrum of latent tuberculosis-existing tests cannot resolve the underlying phenotypes. Nat. Rev. Microbiol. 2010; 8: 242; author reply.
9. Hernandez-Pando R, Orozco H, Aguilar D,. Factors that deregulate the protective immune response in tuberculosis. Arch. Immunol. Ther. Exp. (Warsz) 2009; 57: 355-367.
10. Stewart GR, Robertson BD, Young DB,. Tuberculosis: A problem with persistence. Nat. Rev. Microbiol. 2003; 1: 97-105.
11. Andersson J, Samarina A, Fink J, et al. Impaired expression of perforin and granulysin in CD8+ T cells at the site of infection in human chronic pulmonary tuberculosis. Infect. Immun. 2007; 75: 5210-5222. (Pubitemid 350033607)
12. Stegelmann F, Bastian M, Swoboda K, et al. Coordinate expression of CC chemokine ligand 5, granulysin, and perforin in CD8+ T cells provides a host defense mechanism against Mycobacterium tuberculosis. J. Immunol. 2005; 175: 7474-7483. (Pubitemid 41713445)
13. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N. Engl. J. Med. 2001; 345: 1098-1104.
14. Miller EA, Ernst JD,. Anti-TNF immunotherapy and tuberculosis reactivation: another mechanism revealed. J. Clin. Invest. 2009; 119: 1079-1082.
15. Solovic I, Sester M, Gomez-Reino JJ, et al. The risk of tuberculosis related to tumour necrosis factor antagonist therapies: A TBNET consensus statement. Eur. Respir. J. 2010; 36: 1185-1206.
16. Rueda CM, Marin ND, Garcia LF, et al. Characterization of CD4 and CD8 T cells producing IFN-gamma in human latent and active tuberculosis. Tuberculosis (Edinb) 2010; 90: 346-353.
17. Shen Y, Zhou D, Qiu L, et al. Adaptive immune response of Vgamma2Vdelta2+ T cells during mycobacterial infections. Science 2002; 295: 2255-2258. (Pubitemid 34258837)
18. Shao L, Zhang W, Zhang S, et al. Potent immune responses of Ag-specific Vgamma2Vdelta2+ T cells and CD8+ T cells associated with latent stage of Mycobacterium tuberculosis coinfection in HIV-1-infected humans. AIDS 2008; 22: 2241-2250.
19. Goletti D, Butera O, Bizzoni F, et al. Region of difference 1 antigen-specific CD4+ memory T cells correlate with a favorable outcome of tuberculosis. J. Infect. Dis. 2006; 194: 984-992. (Pubitemid 44454084)
20. Herzmann C, Ernst M, Ehlers S, et al. Increased frequencies of pulmonary Treg cells in latent M. tuberculosis infection. Eur. Respir. J. 2012; doi: 10.1183/09031936.00214611.
21. Chen X, Zhang M, Liao M, et al. Reduced Th17 response in patients with tuberculosis correlates with IL-6R expression on CD4+ T cells. Am. J. Respir. Crit. Care Med. 2010; 181: 734-742.
22. Marin ND, Paris SC, Velez VM, et al. Regulatory T cell frequency and modulation of IFN-gamma and IL-17 in active and latent tuberculosis. Tuberculosis (Edinb) 2010; 90: 252-261.
23. Sester M, Bumbacea D, Duarte R, et al. Tuberculosis in the immunocompromised host. Eur. Resp. Monograph 2012 (in press).
24. Andersen P, Munk ME, Pollock JM, et al. Specific immune-based diagnosis of tuberculosis. Lancet 2000; 356: 1099-1104.
25. Sester U, Wilkens H, van Bentum K, et al. Impaired detection of Mycobacterium tuberculosis immunity in patients using high levels of immunosuppressive drugs. Eur. Respir. J. 2009; 34: 702-710.
26. Diel R, Goletti D, Ferrara G, et al. Interferon-gamma release assays for the diagnosis of latent Mycobacterium tuberculosis infection: A systematic review and meta-analysis. Eur. Respir. J. 2011; 37: 88-99.
27. Pai M, Zwerling A, Menzies D,. Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Ann. Intern. Med. 2008; 149: 177-184.
28. Lalvani A, Pathan AA, Durkan H, et al. Enhanced contact tracing and spatial tracking of Mycobacterium tuberculosis infection by enumeration of antigen-specific T cells. Lancet 2001; 357: 2017-2021. (Pubitemid 32592390)
29. Basu Roy R, Sotgiu G, Altet-Gomez N, et al. Identifying predictors of interferon-gamma release assay results in pediatric latent tuberculosis: A protective role of bacillus Calmette-Guerin?: A pTB-NET collaborative study. Am. J. Respir. Crit. Care Med. 2012; 186: 378-384.
30. Sester M, Sotgiu G, Lange C, et al. Interferon-gamma release assays for the diagnosis of active tuberculosis: A systematic review and meta-analysis. Eur. Respir. J. 2011; 37: 100-111.
31. Kim SH, Lee SO, Park JB, et al. A prospective longitudinal study evaluating the usefulness of a T-cell-based assay for latent tuberculosis infection in kidney transplant recipients. Am. J. Transplant. 2011; 11: 1927-1935.
32. Diel R, Loddenkemper R, Niemann S, et al. Negative and positive predictive value of a whole-blood interferon-γ release assay for developing active tuberculosis: an update. Am. J. Respir. Crit. Care Med. 2011; 183: 88-95.
33. Haldar P, Thuraisingam H, Patel H, et al. Single-step QuantiFERON screening of adult contacts: A prospective cohort study of tuberculosis risk. Thorax 2012; doi: 10.1136/thoraxjnl-2011-200956.
34. Kik SV, Franken WP, Mensen M, et al. Predictive value for progression to tuberculosis by IGRA and TST in immigrant contacts. Eur. Respir. J. 2010; 35: 1346-1353.
35. Leung CC, Yam WC, Yew WW, et al. T-Spot.TB outperforms tuberculin skin test in predicting tuberculosis disease. Am. J. Respir. Crit. Care Med. 2010; 182: 834-840.
36. Jung YJ, Lyu J, Yoo B, et al. Combined use of a TST and the T-SPOT(®).TB assay for latent tuberculosis infection diagnosis before anti-TNF-alpha treatment. Int. J. Tuberc. Lung Dis. 2012; 16: 1300-1306.
37. Vassilopoulos D, Stamoulis N, Hadziyannis E, et al. Usefulness of enzyme-linked immunospot assay (Elispot) compared to tuberculin skin testing for latent tuberculosis screening in rheumatic patients scheduled for anti-tumor necrosis factor treatment. J. Rheumatol. 2008; 35: 1271-1276. (Pubitemid 352000770)
38. Bocchino M, Matarese A, Bellofiore B, et al. Performance of two commercial blood IFN-gamma release assays for the detection of Mycobacterium tuberculosis infection in patient candidates for anti-TNF-alpha treatment. Eur. J. Clin. Microbiol. Infect. Dis. 2008; 27: 907-913.
39. Laffitte E, Janssens JP, Roux-Lombard P, et al. Tuberculosis screening in patients with psoriasis before antitumour necrosis factor therapy: comparison of an interferon-gamma release assay vs. tuberculin skin test. Br. J. Dermatol. 2009; 161: 797-800.
40. Triverio PA, Bridevaux PO, Roux-Lombard P, et al. Interferon-gamma release assays versus tuberculin skin testing for detection of latent tuberculosis in chronic haemodialysis patients. Nephrol. Dial. Transplant. 2009; 24: 1952-1956.
41. Brock I, Ruhwald M, Lundgren B, et al. Latent tuberculosis in HIV positive, diagnosed by the M. tuberculosis specific interferon-gamma test. Respir. Res. 2006; 7: 56.
42. Luetkemeyer AF, Charlebois ED, Flores LL, et al. Comparison of an interferon-gamma release assay with tuberculin skin testing in HIV-infected individuals. Am. J. Respir. Crit. Care Med. 2007; 175: 737-742. (Pubitemid 46536491)
43. Aichelburg MC, Rieger A, Breitenecker F, et al. Detection and prediction of active tuberculosis disease by a whole-blood interferon-gamma release assay in HIV-1-infected individuals. Clin. Infect. Dis. 2009; 48: 954-962.
44. Leung CC, Rieder HL, Lange C, et al. Treatment of latent infection with Mycobacterium tuberculosis: update 2010. Eur. Respir. J. 2011; 37: 690-711.
45. Bumbacea D, Arend SM, Eyuboglu F, et al. The risk of tuberculosis in transplant candidates and recipients: A TBNET consensus statement. Eur. Respir. J. 2012; 40: 990-1013.
46. Kirsch S, Sester M,. Tuberculosis in transplantation: diagnosis, prevention, and treatment. Curr. Infect. Dis. Rep. 2012; 14: 650-657.
47. American Thoracic Society/Infectious Diseases Society of America. Targeted tuberculin testing and treatment of latent tuberculosis infection. Am. J. Respir. Crit. Care Med. 2000; 161: S221-247.
48. Tuberculosis Coalition for Technical Assistance. International Standards for Tuberculosis Care (ISTC), 2nd edn. Tuberculosis Coalition for Technical Assistance, The Hague, 2009.
49. World Health Organization. WHO Policy on Collaborative TB/HIV Activities: Guidelines for National Programmes and Other Stakeholders. World Health Organization, Geneva, 2012.
50. Lobue P, Menzies D,. Treatment of latent tuberculosis infection: an update. Respirology 2010; 15: 603-622.
51. Mount FW, Ferebee SH,. The effect of isoniazid prophylaxis on tuberculosis morbidity among household contacts of previously known cases of tuberculosis. Am. Rev. Respir. Dis. 1962; 85: 821-827.
52. Ferebee SH, Mount FW,. Tuberculosis morbidity in a controlled trial of the prophylactic use of isoniazid among household contacts. Am. Rev. Respir. Dis. 1962; 85: 490-510.
53. Ferebee SH, Mount FW, Murray FJ, et al. A controlled trial of isoniazid prophylaxis in mental institutions. Am. Rev. Respir. Dis. 1963; 88: 161-175.
54. Comstock GW, Ferebee SH, Hammes LM,. A controlled trial of community-wide isoniazid prophylaxis in Alaska. Am. Rev. Respir. Dis. 1967; 95: 935-943.
55. International Union Against Tuberculosis Committee on Prophylaxis. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. Bull. World Health Organ. 1982; 60: 555-564.
56. Snider DE, Jr, Caras GJ, Koplan JP,. Preventive therapy with isoniazid. Cost-effectiveness of different durations of therapy. JAMA 1986; 255: 1579-1583. (Pubitemid 16167478)
57. Comstock GW,. How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults? Int. J. Tuberc. Lung Dis. 1999; 3: 847-850. (Pubitemid 29488035)
58. American Thoracic Society. Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR Recomm. Rep. 2000; 49: 1-51.
59. Smieja MJ, Marchetti CA, Cook DJ, et al. Isoniazid for preventing tuberculosis in non-HIV infected persons. Cochrane Database Syst. Rev. 2000; (1): CD001363.
60. Garibaldi RA, Drusin RE, Ferebee SH, et al. Isoniazid-associated hepatitis. Report of an outbreak. Am. Rev. Respir. Dis. 1972; 106: 357-365.
61. Kopanoff DE, Snider DE, Jr, Caras GJ,. Isoniazid-related hepatitis: A U.S. Public Health Service cooperative surveillance study. Am. Rev. Respir. Dis. 1978; 117: 991-1001. (Pubitemid 8380195)
62. Steele MA, Burk RF, DesPrez RM,. Toxic hepatitis with isoniazid and rifampin. A meta-analysis. Chest 1991; 99: 465-471.
63. Nolan CM, Goldberg SV, Buskin SE,. Hepatotoxicity associated with isoniazid preventive therapy: A 7-year survey from a public health tuberculosis clinic. JAMA 1999; 281: 1014-1018. (Pubitemid 29143893)
64. LoBue PA, Moser KS,. Use of isoniazid for latent tuberculosis infection in a public health clinic. Am. J. Respir. Crit. Care Med. 2003; 168: 443-447. (Pubitemid 37046873)
65. Hong Kong Chest Service/Tuberculosis Research Centre, Madras/British Medical Research Council. A double-blind placebo-controlled clinical trial of three antituberculosis chemoprophylaxis regimens in patients with silicosis in Hong Kong. Am. Rev. Respir. Dis. 1992; 145: 36-41.
66. National Institute for Health and Clinical Excellence. Tuberculosis: clinical diagnosis and management of tuberculosis, and measures for its prevention and control. 2011. [Accessed 15 Nov 2012.] Available from URL: http://guidance.nice.org.uk/CG117/NICEGuidance/pdf/English
67. Ziakas PD, Mylonakis E,. 4 months of rifampin compared with 9 months of isoniazid for the management of latent tuberculosis infection: A meta-analysis and cost-effectiveness study that focuses on compliance and liver toxicity. Clin. Infect. Dis. 2009; 49: 1883-1889.
68. Menzies D,. A randomized clinical trial comparing 4RIF vs 9INH for treatment of latent tuberculosis infection (LTBI)-effectiveness. 2012. [Accessed 10 Sep 2012.] Available from URL: http://clinicaltrials.gov/ct2/show/ NCT00931736
69. Ena J, Valls V,. Short-course therapy with rifampin plus isoniazid, compared with standard therapy with isoniazid, for latent tuberculosis infection: A meta-analysis. Clin. Infect. Dis. 2005; 40: 670-676. (Pubitemid 40381339)
70. Jasmer RM, Snyder DC, Chin DP, et al. Twelve months of isoniazid compared with four months of isoniazid and rifampin for persons with radiographic evidence of previous tuberculosis: an outcome and cost-effectiveness analysis. Am. J. Respir. Crit. Care Med. 2000; 162: 1648-1652.
71. Spyridis NP, Spyridis PG, Gelesme A, et al. The effectiveness of a 9-month regimen of isoniazid alone versus 3- and 4-month regimens of isoniazid plus rifampin for treatment of latent tuberculosis infection in children: results of an 11-year randomized study. Clin. Infect. Dis. 2007; 45: 715-722. (Pubitemid 47378885)
72. Whalen CC, Johnson JL, Okwera A, et al. A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. Uganda-Case Western Reserve University Research Collaboration. N. Engl. J. Med. 1997; 337: 801-808. (Pubitemid 27391629)
73. Mwinga A, Hosp M, Godfrey-Faussett P, et al. Twice weekly tuberculosis preventive therapy in HIV infection in Zambia. AIDS 1998; 12: 2447-2457. (Pubitemid 28558603)
74. Halsey NA, Coberly JS, Desormeaux J, et al. Randomised trial of isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection. Lancet 1998; 351: 786-792. (Pubitemid 28112340)
75. Gordin F, Chaisson RE, Matts JP, et al. Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health Organization, and the Centers for Disease Control and Prevention Study Group. JAMA 2000; 283: 1445-1450.
76. American Thoracic Society/Centers of Disease Control and Prevention. Update: adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection-United States, 2003. MMWR Morb. Mortal. Wkly Rep. 2003; 52: 735-739.
77. Schechter M, Zajdenverg R, Falco G, et al. Weekly rifapentine/isoniazid or daily rifampin/pyrazinamide for latent tuberculosis in household contacts. Am. J. Respir. Crit. Care Med. 2006; 173: 922-926.
78. Martinson NA, Barnes GL, Moulton LH, et al. New regimens to prevent tuberculosis in adults with HIV infection. N. Engl. J. Med. 2011; 365: 11-20.
79. Sterling TR, Villarino ME, Borisov AS, et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N. Engl. J. Med. 2011; 365: 2155-2166.
80. Centers of Disease Control and Prevention. Recommendations for use of an isoniazid-rifapentine regimen with direct observation to treat latent Mycobacterium tuberculosis infection. MMWR Morb. Mortal. Wkly Rep. 2011; 60: 1650-1653.
81. Bucher HC, Griffith LE, Guyatt GH, et al. Isoniazid prophylaxis for tuberculosis in HIV infection: A meta-analysis of randomized controlled trials. AIDS 1999; 13: 501-507.
82. Akolo C, Adetifa I, Shepperd S, et al. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst. Rev. 2010; (1): CD000171.
83. Johnson JL, Okwera A, Hom DL, et al. Duration of efficacy of treatment of latent tuberculosis infection in HIV-infected adults. AIDS 2001; 15: 2137-2147. (Pubitemid 33101821)
84. Quigley MA, Mwinga A, Hosp M, et al. Long-term effect of preventive therapy for tuberculosis in a cohort of HIV-infected Zambian adults. AIDS 2001; 15: 215-222. (Pubitemid 32142297)
85. Samandari T, Agizew TB, Nyirenda S, et al. 6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: A randomised, double-blind, placebo-controlled trial. Lancet 2011; 377: 1588-1598.
86. World Health Organization. Guidelines for Intensified Tuberculosis Case-Finding and Isoniazid Preventive Therapy for People Living with HIV in Resource-Constrained Settings. World Health Organization, Geneva, 2011.
87. Polesky A, Farber HW, Gottlieb DJ, et al. Rifampin preventive therapy for tuberculosis in Boston's homeless. Am. J. Respir. Crit. Care Med. 1996; 154: 1473-1477. (Pubitemid 26391200)
88. Villarino ME, Ridzon R, Weismuller PC, et al. Rifampin preventive therapy for tuberculosis infection: experience with 157 adolescents. Am. J. Respir. Crit. Care Med. 1997; 155: 1735-1738. (Pubitemid 27216686)
89. van der Werf MJ, Langendam MW, Sandgren A, et al. Lack of evidence to support policy development for management of contacts of multidrug-resistant tuberculosis patients: two systematic reviews. Int. J. Tuberc. Lung Dis. 2012; 16: 288-296.
90. Centers of Disease Control and Prevention. Management of persons exposed to multidrug-resistant tuberculosis. MMWR Recomm. Rep. 1992; 41: 61-71.
91. Lou HX, Shullo MA, McKaveney TP,. Limited tolerability of levofloxacin and pyrazinamide for multidrug-resistant tuberculosis prophylaxis in a solid organ transplant population. Pharmacotherapy 2002; 22: 701-704. (Pubitemid 34596478)
92. Papastavros T, Dolovich LR, Holbrook A, et al. Adverse events associated with pyrazinamide and levofloxacin in the treatment of latent multidrug-resistant tuberculosis. CMAJ 2002; 167: 131-136. (Pubitemid 34791519)
93. Younossian AB, Rochat T, Ketterer JP, et al. High hepatotoxicity of pyrazinamide and ethambutol for treatment of latent tuberculosis. Eur. Respir. J. 2005; 26: 462-464. (Pubitemid 41264210)
94. Curry International Tuberculosis Center and California Department of Public Health. Drug-Resistant Tuberculosis: A Survival Guide for Clinicians, 2nd edn. Curry International Tuberculosis Centre, California Department of Public Health, San Francisco, CA, 2008.
95. Seddon JA, Godfrey-Faussett P, Hesseling AC, et al. Management of children exposed to multidrug-resistant Mycobacterium tuberculosis. Lancet Infect. Dis. 2012; 12: 469-479.
96. Stop TB Partnership Childhood TB subgroup. Chapter 4: childhood contact screening and management. Int. J. Tuberc. Lung Dis. 2007; 11: 12-15.
97. European Centre for Disease Prevention and Control. Management of Contacts of MDR TB and XDR TB Patients. ECDC, Stockholm, 2012.
98. Sester U, Fousse M, Dirks J, et al. Whole-blood flow-cytometric analysis of antigen-specific CD4 T-cell cytokine profiles distinguishes active tuberculosis from non-active states. PLoS ONE 2011; 6: e17813.
99. Harari A, Rozot V, Enders FB, et al. Dominant TNF-alpha+ Mycobacterium tuberculosis-specific CD4+ T cell responses discriminate between latent infection and active disease. Nat. Med. 2011; 17: 372-376.
100. Lange C, Sester M,. TB or not TB: the role of immunodiagnosis. Eur. J. Immunol. 2012; 42: 2840-2843.
101. Millington KA, Innes JA, Hackforth S, et al. Dynamic relationship between IFN-gamma and IL-2 profile of Mycobacterium tuberculosis-specific T cells and antigen load. J. Immunol. 2007; 178: 5217-5226. (Pubitemid 46595306)
102. Krummel B, Strassburg A, Ernst M, et al. Potential role for IL-2 ELISpot in differentiating recent and remote infection in tuberculosis contact tracing. PLoS ONE 2010; 5: e11670.
103. Casey R, Blumenkrantz D, Millington K, et al. Enumeration of functional T-cell subsets by fluorescence-immunospot defines signatures of pathogen burden in tuberculosis. PLoS ONE 2010; 5: e15619.
104. Ruhwald M, Dominguez J, Latorre I, et al. A multicentre evaluation of the accuracy and performance of IP-10 for the diagnosis of infection with M. tuberculosis. Tuberculosis (Edinb.) 2011; 91: 260-267.
105. Ruhwald M, Ravn P,. Biomarkers of latent TB infection. Expert. Rev. Respir. Med. 2009; 3: 387-401.
106. Ruhwald M, Aabye MG, Ravn P,. IP-10 release assays in the diagnosis of tuberculosis infection: current status and future directions. Expert. Rev. Mol. Diagn. 2012; 12: 175-187.
107. Berry MP, Graham CM, McNab FW, et al. An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis. Nature 2010; 466: 973-977.
108. Lu C, Wu J, Wang H, et al. Novel biomarkers distinguishing active tuberculosis from latent infection identified by gene expression profile of peripheral blood mononuclear cells. PLoS ONE 2011; 6: e24290.
109. Maertzdorf J, Weiner J III, Kaufmann SH,. Enabling biomarkers for tuberculosis control. Int. J. Tuberc. Lung Dis. 2012; 16: 1140-1148.
110. Selgrad M, Kandulski A, Malfertheiner P,. Helicobacter pylori: diagnosis and treatment. Curr. Opin. Gastroenterol. 2009; 25: 549-556.
111. Marks SM, Taylor Z, Qualls NL, et al. Outcomes of contact investigations of infectious tuberculosis patients. Am. J. Respir. Crit. Care Med. 2000; 162: 2033-2038. (Pubitemid 32051659)
112. Comstock GW, Ferebee SH,. How much isoniazid is needed for prophylaxis? Am. Rev. Respir. Dis. 1970; 101: 780-782.
113. Diel R, Loddenkemper R, Meywald-Walter K, et al. Predictive value of a whole blood IFN-gamma assay for the development of active tuberculosis disease after recent infection with Mycobacterium tuberculosis. Am. J. Respir. Crit. Care Med. 2008; 177: 1164-1170. (Pubitemid 351717577)
114. Lange C, Rieder HL,. Intention to test is intention to treat. Am. J. Respir. Crit. Care Med. 2011; 183: 3-4.